Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 7 sources · 30 days · First seen about 1 month ago · Last updated 3 days ago

Moderna financial and research developments

Overview

Moderna experienced significant market and operational shifts in late 2026. In October, company shares reached a four year high following news of a planned public-private partnership with the National Institutes of Health and other institutions to accelerate cancer vaccine development. This initiative, modeled after COVID-19 pandemic collaborations, was expected to launch in December.

By November, Moderna reported third quarter 2026 financial results showing a return to profitability with a net profit of $162 million, compared to a loss in the same period the previous year. Revenue rose 29 percent to $1.31 billion, driven largely by international demand for COVID-19 vaccines. During this period, the company also noted progress in its oncology and infectious disease pipelines, including plans to present data on multiple myeloma therapy and a recommendation for its Ebola vaccine candidate to enter Phase 2/3 trials.

Entities

Merck · Moderna · Bank of America · Nasdaq-100 · World Health Organization

Claims

What the coverage asserts, and how many sources carry each claim.

[● 2 SOURCES] Moderna reported Q3 2026 revenue of $1.31 billion. bitfinanzas.com · stockstory.org
[● 2 SOURCES] Revenue increased by 29% year-on-year. bitfinanzas.com · stockstory.org
[● 2 SOURCES] GAAP diluted earnings per share was $0.38. bitfinanzas.com · stockstory.org
[○ 1 SOURCE] Moderna recorded a net profit of $162 million in Q3 2026. bitfinanzas.com
[○ 1 SOURCE] Moderna raised annual revenue projections to a range of 15% to 25% for the end of 2026. bitfinanzas.com
[○ 1 SOURCE] The WHO advisory group recommended Moderna's Ebola vaccine candidate, mRNA-1469, be included in a Phase 2/3 trial in the Democratic Republic of the Congo. www.financial-news.co.uk
[○ 1 SOURCE] Moderna's stock rose 13% in a single session on November 4. www.financial-news.co.uk
[○ 1 SOURCE] Intismeran combined with Merck's Keytruda showed a 42% lower relative risk of melanoma recurrence or death in published findings. www.financial-news.co.uk

Timeline

3 days ago

[BUSINESS] 7 sources
Moderna reports $1.31 billion in Q3 2026 revenue and returns to profitability
Moderna reported Q3 2026 revenue of $1.31 billion, a 29% year-on-year increase, returning to a net profit of $162 million.
about 1 month ago

[BUSINESS] 9 sources
Moderna shares hit four-year high on cancer vaccine news
Moderna shares hit a four-year high following news of a planned NIH-backed public-private partnership to accelerate cancer vaccine development and the company's return to the Nasdaq-100 index.

Sources

bitfinanzas.com · cashcow.nl · diarioestrategia.cl · financial-news.co.uk · ibtimes.com.au · tecnologia-informatica.com · unilorin.edu.ng